34
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Accelerated pre‐senile systemic amyloidosis in PACAP knockout mice – a protective role of PACAP in age‐related degenerative processes

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Dysregulation of neuropeptides may play an important role in aging‐induced impairments. Among them, pituitary adenylate cyclase‐activating polypeptide (PACAP) is a potent cytoprotective peptide that provides an endogenous control against a variety of tissue‐damaging stimuli. We hypothesized that the progressive decline of PACAP throughout life and the well‐known general cytoprotective effects of PACAP lead to age‐related pathophysiological changes in PACAP deficiency, supported by the increased vulnerability to various stressors of animals partially or totally lacking PACAP. Using young and aging CD1 PACAP knockout (KO) and wild type (WT) mice, we demonstrated pre‐senile amyloidosis in young PACAP KO animals and showed that senile amyloidosis appeared accelerated, more generalized, more severe, and affected more individuals. Histopathology showed age‐related systemic amyloidosis with mainly kidney, spleen, liver, skin, thyroid, intestinal, tracheal, and esophageal involvement. Mass spectrometry‐based proteomic analysis, reconfirmed with immunohistochemistry, revealed that apolipoprotein‐AIV was the main amyloid protein in the deposits together with several accompanying proteins. Although the local amyloidogenic protein expression was disturbed in KO animals, no difference was found in laboratory lipid parameters, suggesting a complex pathway leading to increased age‐related degeneration with amyloid deposits in the absence of PACAP. In spite of no marked inflammatory histological changes or blood test parameters, we detected a disturbed cytokine profile that possibly creates a pro‐inflammatory milieu favoring amyloid deposition. In summary, here we describe accelerated systemic senile amyloidosis in PACAP gene‐deficient mice, which might indicate an early aging phenomenon in this mouse strain. Thus, PACAP KO mice could serve as a model of accelerated aging with human relevance. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

          Related collections

          Most cited references74

          • Record: found
          • Abstract: not found
          • Article: not found

          The systemic amyloidoses.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene.

            The tissue amyloid deposits that characterize systemic amyloidosis, Alzheimer's disease and the transmissible spongiform encephalopathies always contain serum amyloid P component (SAP) bound to the amyloid fibrils. We have previously proposed that this normal plasma protein may contribute to amyloidogenesis by stabilizing the deposits. Here we show that the induction of reactive amyloidosis is retarded in mice with targeted deletion of the SAP gene. This first demonstration of the participation of SAP in pathogenesis of amyloidosis in vivo confirms that inhibition of SAP binding to amyloid fibrils is an attractive therapeutic target in a range of serious human diseases.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pituitary adenylate cyclase-activating polypeptide protects against β-amyloid toxicity.

              Pituitary adenylate cyclase activating polypeptide (PACAP) is a neurotrophin. However, its role in human Alzheimer's disease (AD) is largely unknown. We examined PACAP expression in postmortem human AD and triple transgenic mouse (3xTG, Psen1/APPSwe/TauP301L) brains. We established an in vitro model of primary neuronal cell culture to study the protective effects of PACAP against β-amyloid (Aβ) toxicity. We further studied the PACAP-Sirtuin 3 (Sirt3) pathway on mitochondrial function. PACAP expression was reduced in AD and 3xTG mouse brains. This reduction was inversely correlated with Aβ and tau protein levels. Treatment with PACAP effectively protected neurons against Aβ toxicity. PACAP stimulated mitochondrial Sirt3 production. Similar to PACAP, Sirt3 was reduced in AD and 3xTG brains. Knocking down Sirt3 compromised the neuroprotective effects of PACAP, and this was reversed by over-expressing Sirt3. PACAP is reduced in AD and may represent a novel therapeutic strategy.
                Bookmark

                Author and article information

                Contributors
                abardosi@web.de
                Journal
                J Pathol
                J. Pathol
                10.1002/(ISSN)1096-9896
                PATH
                The Journal of Pathology
                John Wiley & Sons, Ltd (Chichester, UK )
                0022-3417
                1096-9896
                04 July 2018
                August 2018
                : 245
                : 4 ( doiID: 10.1002/path.2018.245.issue-4 )
                : 478-490
                Affiliations
                [ 1 ] Department of Anatomy, MTA‐PTE PACAP Research Group University of Pecs Medical School Pécs Hungary
                [ 2 ] Institute of Pathology University of Heidelberg Heidelberg Germany
                [ 3 ] Center for Histology Cytology and Molecular Diagnostics Trier Germany
                [ 4 ] Proteopath GmbH Trier Germany
                [ 5 ] Department of Anatomy, Histology and Embryology, Faculty of Medicine University of Debrecen Hungary
                [ 6 ] Department of Biochemistry and Medical Chemistry University of Pecs Medical School Pécs Hungary
                [ 7 ] Second Department of Internal Medicine University of Pecs Medical School Pécs Hungary
                [ 8 ] Department of Laboratory Medicine and Szentagothai Research Centre University of Pecs Medical School Pécs Hungary
                [ 9 ] Laboratory of Mass Spectrometry (LSM) – MolSys, Department of Chemistry University of Liège Belgium
                [ 10 ] Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences Osaka University Japan
                Author notes
                [*] [* ]Correspondence to: Attila Bardosi, Center for Histology, Cytology and Molecular Diagnostics, Max‐Planck‐Strasse 5, 54296 Trier, Germany. E‐mail: abardosi@ 123456web.de
                Author information
                http://orcid.org/0000-0002-7319-3646
                http://orcid.org/0000-0002-2791-7017
                Article
                PATH5100
                10.1002/path.5100
                6055756
                29774542
                6e3f8b0a-c146-4c51-be35-15eb9b0d7bd6
                © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 15 December 2017
                : 10 April 2018
                : 12 May 2018
                Page count
                Figures: 6, Tables: 1, Pages: 13, Words: 7466
                Funding
                Funded by: National Development Plan
                Award ID: GINOP‐2.3.2‐15‐2016‐00050
                Funded by: Hungarian Academy of Sciences
                Award ID: MTA‐TKI14016
                Funded by: Hungarian National Science Research Fund
                Award ID: NKFIH K119759
                Award ID: 115874
                Funded by: PTE ÁOK KA Research Grant
                Funded by: Bolyai Scholarship and New Excellence Program
                Funded by: New National Excellence Program of the Ministry of Human Capacities
                Award ID: UNKP-16-4-IV
                Funded by: National Excellence Program TAMOP
                Award ID: 4.2.4.A/2-11-1-2012-0001
                Funded by: JSPS KAKENHI
                Award ID: JP26293020
                Award ID: JP17H03989
                Award ID: JP17K19488
                Funded by: SRPBS and Brain/MINDS
                Award ID: EFOP‐3.6.3‐VEKOP‐16‐15 2017‐00008
                Funded by: ‘The role of neuro‐inflammation in neurodegeneration: from molecules to clinics’
                Funded by: Szodoray Lajos and Magyary Zoltan Funds
                Funded by: Hungarian Academy of Science and the European Union and the State of Hungary
                Funded by: European Social Fund
                Award ID: TÁMOP 4.2.4
                Categories
                Original Paper
                Original Papers
                Custom metadata
                2.0
                path5100
                August 2018
                Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.3 mode:remove_FC converted:23.07.2018

                Pathology
                amyloid,apolipoprotein‐aiv,maldi imaging,proteomic analysis
                Pathology
                amyloid, apolipoprotein‐aiv, maldi imaging, proteomic analysis

                Comments

                Comment on this article